What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
- 31 August 2005
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet Oncology
- Vol. 6 (8), 581-588
- https://doi.org/10.1016/s1470-2045(05)70254-0
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association StudyJournal of Clinical Oncology, 2002
- Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile?The Lancet Oncology, 2001
- Effect of Endocrine Treatment on Sexuality in Premenopausal Breast Cancer Patients: A Prospective Randomized StudyJournal of Clinical Oncology, 2001
- Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?The Lancet, 2000
- Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT‐BBreast Cancer Research and Treatment, 1999
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Life after breast cancer: understanding women's health-related quality of life and sexual functioning.Journal of Clinical Oncology, 1998
- Ovarian ablation in early breast cancer: overview of the randomised trialsThe Lancet, 1996
- Breast irradiation postlumpectomy: development and evaluation of a decision instrument.Journal of Clinical Oncology, 1995
- A Bedside Decision Instrument To Elicit a Patient's Preference Concerning Adjuvant Chemotherapy for Breast CancerAnnals of Internal Medicine, 1992